Vadim Baidin

Vadim Baidin

Auto-generated profile, based on publicly available information

Vadim Baidin

Department of Chemistry and Chemical Biology, Harvard University, Cambridge, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
3 January 2024 in Nature
Verified
Journal Article
Open access
PDF file
CZClaudia Zampaloni
Claudia Zampaloni
PMPatrizio Mattei
Patrizio Mattei
KBKonrad Bleicher
Konrad Bleicher
LWLotte Winther
Lotte Winther
CTClaudia Thäte
Claudia Thäte
KBKenneth A. Bradley
Kenneth A. Bradley
Carbapenem-resistant Acinetobacter baumannii (CRAB) has emerged as a major global pathogen with limited treatment options1. No new antibiotic chemical class with activity against A. baumannii has reached patients in over 50 years1. Here we report the identification and optimization of tethered macrocyclic peptide (MCP) antibiotics with potent antibacterial activity against CRAB. The mechanism of action of this molecule class involves blocking the transport of bacterial lipopolysaccharide from the inner membrane to its destination on the outer membrane, through inhibition of the LptB2FGC complex. A clinical candidate derived from the MCP class, zosurabalpin (RG6006), effectively treats highly drug-resistant contemporary isolates of CRAB both in vitro and in mouse models of infection, overcoming existing antibiotic resistance mechanisms. This chemical class represents a promising treatment paradigm for patients with invasive infections due to CRAB, for whom current treatment options are inadequate, and additionally identifies LptB2FGC as a tractable target for antimicrobial drug development.

3 January 2024 in Nature
Verified
Journal Article
Open access
PDF file
KPKaranbir S. Pahil
Karanbir S. Pahil
MGMorgan S. A. Gilman
Morgan S. A. Gilman
VBVadim Baidin
Vadim Baidin
TCThomas Clairfeuille
Thomas Clairfeuille
PMPatrizio Mattei
Patrizio Mattei
DKDaniel Kahne
Daniel Kahne
Gram-negative bacteria are extraordinarily difficult to kill because their cytoplasmic membrane is surrounded by an outer membrane that blocks the entry of most antibiotics. The impenetrable nature of the outer membrane is due to the presence of a large, amphipathic glycolipid called lipopolysaccharide (LPS) in its outer leaflet1. Assembly of the outer membrane requires transport of LPS across a protein bridge that spans from the cytoplasmic membrane to the cell surface. Maintaining outer membrane integrity is essential for bacterial cell viability, and its disruption can increase susceptibility to other antibiotics2–6. Thus, inhibitors of the seven lipopolysaccharide transport (Lpt) proteins that form this transenvelope transporter have long been sought7–9. A new class of antibiotics that targets the LPS transport machine in Acinetobacter was recently identified. Here, using structural, biochemical and genetic approaches, we show that these antibiotics trap a substrate-bound conformation of the LPS transporter that stalls this machine. The inhibitors accomplish this by recognizing a composite binding site made up of both the Lpt transporter and its LPS substrate. Collectively, our findings identify an unusual mechanism of lipid transport inhibition, reveal a druggable conformation of the Lpt transporter and provide the foundation for extending this class of antibiotics to other Gram-negative pathogens.

7 May 2018 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
GZGe Zhang
Ge Zhang
VBVadim Baidin
Vadim Baidin
KPKaranbir S. Pahil
Karanbir S. Pahil
EMEileen Moison
Eileen Moison
DTDavid Tomasek
David Tomasek
DKDaniel Kahne
Daniel Kahne
New drugs are needed to treat gram-negative bacterial infections. These bacteria are protected by an outer membrane which prevents many antibiotics from reaching their cellular targets. The outer leaflet of the outer membrane contains LPS, which is responsible for creating this permeability barrier. Interfering with LPS biogenesis affects bacterial viability. We developed a cell-based screen that identifies inhibitors of LPS biosynthesis and transport by exploiting the nonessentiality of this pathway in Acinetobacter. We used this screen to find an inhibitor of MsbA, an ATP-dependent flippase that translocates LPS across the inner membrane. Treatment with the inhibitor caused mislocalization of LPS to the cell interior. The discovery of an MsbA inhibitor, which is universally conserved in all gram-negative bacteria, validates MsbA as an antibacterial target. Because our cell-based screen reports on the function of the entire LPS biogenesis pathway, it could be used to identify compounds that inhibit other targets in the pathway, which can provide insights into vulnerabilities of the gram-negative cell envelope. Significance The outer membrane of gram-negative bacteria contains LPS on the cell surface. The presence of LPS creates an effective permeability barrier that protects gram-negative bacteria from small hydrophobic molecules. Because the entire LPS biogenesis pathway, including biosynthesis and transport, is highly conserved, proteins involved are attractive targets for antibiotic discovery. Historically, it has been challenging to target LPS biogenesis since many of the components are membrane proteins with hard-to-assay activities. Utilizing the nonessentiality of this pathway in a gram-negative pathogen, we developed a cell-based screen specific to LPS biogenesis. We identified a small-molecule inhibitor targeting an essential component of the pathway, MsbA, and validated it as an antibacterial target using a combination of genetics, biochemistry, and cellular assays.

1 January 2019 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
JBJackson A. Buss
Jackson A. Buss
VBVadim Baidin
Vadim Baidin
MWMichael A. Welsh
Michael A. Welsh
JFJosué Flores-Kim
Josué Flores-Kim
HCHongbaek Cho
Hongbaek Cho
TBThomas G. Bernhardt
Thomas G. Bernhardt
New antibiotics are needed to combat the growing problem of resistant bacterial infections. An attractive avenue towards the discovery of such next generation therapies is to identify novel inhibitors of clinically validated targets like cell wall biogenesis. We have therefore developed a pathway-directed, whole-cell screen for small molecules that block the activity of the Rod system of Escherichia coli. This conserved multi-protein complex is required for cell elongation and the morphogenesis of rod-shaped bacteria. It is composed of cell wall synthases and membrane proteins of unknown function that are organized by filaments of the actin-like MreB protein. Our screen takes advantage of the conditional essentiality of the Rod system and the ability of the beta-lactam mecillinam to cause a toxic malfunctioning of the machinery. Rod system inhibitors can therefore be identified as molecules that promote growth in the presence of mecillinam under conditions permissive for the growth of Rod– cells. A screen of ∼690,000 identified 1,300 compounds active against E. coli. Pathway-directed screening of a majority of this subset of compounds for Rod inhibitors successfully identified eight analogs of the MreB-antagonist A22. Further characterization of the A22 analogs identified showed that their antibiotic activity under conditions where the Rod system is essential was strongly correlated with their ability to suppress mecillinam toxicity. This result combined with additional biological studies reinforce the notion that A22-like molecules are relatively specific for MreB and suggest that the lipoprotein transport factor LolA is unlikely to be a physiologically relevant target as previously proposed.

11 May 2023 in Angewandte Chemie International Edition
Verified
Journal Article
Closed access
YPYoungseon Park
Youngseon Park
ATAtsushi Taguchi
Atsushi Taguchi
VBVadim Baidin
Vadim Baidin
DKDaniel Kahne
Daniel Kahne
SWSuzanne Walker
Suzanne Walker

11 July 2024 in Nature
Verified
Journal Article
Open access
PDF file
CZClaudia Zampaloni
Claudia Zampaloni
PMPatrizio Mattei
Patrizio Mattei
KBKonrad Bleicher
Konrad Bleicher
LWLotte Winther
Lotte Winther
CTClaudia Thäte
Claudia Thäte
KBKenneth A. Bradley
Kenneth A. Bradley